Navigation Links
2008 a Record Year for Gerresheimer
Date:4/29/2009

DUSSELDORF, Germany, April 29 /PRNewswire-FirstCall/ --

- Strong Focus on the Markets of Pharma & Life Science

- Annual General Meeting Passes Dividend of EUR0.40 per Share

The Annual General Meeting of Gerresheimer AG today passed an unchanged dividend of EUR0.40 per share following the record year in 2008.

The Company finished the financial year 2008 with record results. Gerresheimer achieved sales of EUR1.06 billion (prior year EUR957.7m) and operating results (adjusted EBITDA) of EUR206.4m (prior year EUR181.6m).

At the Annual General Meeting in Dusseldorf the CEO Dr. Axel Herberg summarized the highlights of the financial year 2008: "We have achieved record levels in terms of sales and earnings. Gerresheimer is on a good course and will show itself to be very robust even in times of crisis."

The shareholders approved the actions of the members of the Company's Supervisory Board and Management Board for the financial year 2008 and, as in the prior year, passed a dividend payment of EUR0.40 per share.

With share capital representation of 59.44% the Annual General Meeting passed the following resolutions:

ITEM 2: Appropriation of net earnings for the financial year 2008:

(99.99% of votes in favor)

ITEM 3: Approval of the actions of the Management Board members for the financial year 2008:

(100% of votes in favor)

ITEM 4: Approval of the actions of the Supervisory Board members for the financial year 2008:

(100% of votes in favor)

ITEM 5: Supplementary election to the Supervisory Board of Mr. Theodor Stuth, Auditor and Certified Tax Advisor, Neuss:

    (100% of votes in favor)
    ITEM 6: Election of the auditor for the financial year 2009:
    (99.99% of votes in favor)
    The speech is available onhttp://www.gerresheimer.com/en/press.html.
    About Gerresheimer

Gerresheimer employs around 10,000 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharma­ceu­tical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.(WKN: 587300)

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax   +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax   +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Globus Medical Announces Record 2nd Quarter 2007 Results
2. BioSpace Draws Record Crowd to Chicago Life Science Career Fair
3. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
4. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
5. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. China Biologic Products Reports Record Third Quarter 2007 Results
8. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
9. The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
10. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... Wayne. NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a ... rinse one eye at a time. So which eye do you rinse first if a ... you have Plum Duo Eye Wash with its unique dual eye piece. , ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):